

Pharmaceutical Policies Updates Effective June 1, 2022

To view all current MVP Health Care® (MVP) Medical policies, *Sign In* at mvphealthcare.com and select *Resources*, then *Medical Policies*. All policies are reviewed at least once annually. This communication lists all impacted policies and their status. Policies fall into one of the following categories:

- **New** – Denotes a new policy
- **Updated** – Updated policies have content changes that may affect coverage criteria for services and/or drugs
- **Reviewed/No Changes**– Policies that have been reviewed but have no content change
- **Archived** – Denotes a policy that is no longer active

The following policies are effective June 1, 2022 and will be available for viewing on or before May 1, 2022. Hard copies of the policies are available upon request.

Pharmaceutical Policy Name	Status
Valchlor	Reviewed/No Changes
Eylea	Reviewed/No Changes
Topical Agents for Pruritus	Reviewed/No Changes
Cosmetic Drug Agents	Updated
Psoriasis Drug Therapy	Updated
Psoriatic Arthritis Drug Therapy- Effective April 1, 2022	Updated
Onychomycosis	Reviewed/No Changes
Duchenne Muscular Dystrophy- Effective April 1, 2022	Updated
Formulary Exception For Non-Covered Drug - Effective April 1, 2022	Updated
CAR-T Cell Therapy	Updated
Drug Utilization Review and Monitoring Program	Reviewed/No Changes
Luxturna	Reviewed/No Changes
Parsabiv	Updated
Preventive Services-Medication - Effective April 1, 2022	Updated
Pain Medications- Effective March 22, 2022	Updated

To view all communications, visit mvphealthcare.com/FastFax

Questions? Contact your MVP Professional Relations Representative or call the MVP Customer Care Center for Provider Services at 1-800-684-9286.

